NCT05572645View on ClinicalTrials.gov

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

CompletedOBSERVATIONAL
Enrollment

333

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Breast Cancer
Interventions
DRUG

Pyrotinib Plus Trastuzumab

treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

DRUG

Pertuzumab Plus Trastuzumab

treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER